Trials testing a treatment · 5 studies
Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.
Untreated metastatic colorectal cancer with a KRAS G12C mutation: sotorasib and panitumumab added to chemotherapy
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.
For: Metastatic Colorectal Cancer
6 centres: Institutul Clinic Fundeni, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca, Cluj-Napoca · Centrul de Oncologie Sf Nectarie SRL, Craiova · and 3 more
Phase 3See the official record ↗NCT06252649
Original registry title
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Colorectal cancer without KRAS, NRAS and BRAF mutations, after chemotherapy: amivantamab compared with cetuximab or bevacizumab
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
For: Colorectal Neoplasms
6 centres: Centrul Medical Unirea SRL, Brașov · Spitalul Memorial Baneasa, București · Institutul Oncologic 'Prof Dr. Ion Chiricuta' Cluj-Napoca, Cluj-Napoca · and 3 more
Phase 3See the official record ↗NCT06750094
Original registry title
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Untreated metastatic colorectal cancer: a new medicine with chemotherapy compared with bevacizumab with chemotherapy
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
For: Untreated, Unresectable, or Metastatic Colorectal Cancer
5 centres: Fundeni Clinical Institute, București · Institutul Regional de Gastroenterologie și Hepatologie Prof. Dr. Octavian Fodor, Cluj-Napoca · Centrul de Oncologie "Sfântul Nectarie", Craiova · and 2 more
Phase 2See the official record ↗NCT07221357
Original registry title
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Colorectal cancer: calderasib added to targeted therapy and chemotherapy
Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C.
Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding calderasib (the study medicine) and cetuximab to mFOLFOX6 can treat locally advanced or mCRC with the KRAS G12C mutation. Calderasib and cetuximab are targeted therapies.
The goals of this study are to learn:
* About the safety of calderasib with cetuximab and mFOLFOX6 and if people tolerate the treatments
* If people who receive calderasib with cetuximab and mFOLFOX6 live longer without mCRC growing or spreading compared to people who receive mFOLFOX6 with or without bevacizumab.
For: Colon Adenocarcinoma, Rectal Adenocarcinoma
4 centres: Fundeni Clinical Institute-Medical Oncology, București · Institutul Oncologic Cluj, Cluj-Napoca · Centrul de Oncologie Sfantul Nectarie-Medical, Craiova · and 1 more
Phase 3See the official record ↗NCT06997497
Original registry title
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Colorectal cancer surgery: two types of anaesthesia compared for their effect on muscle mass
This study is aimed at clarifying changes in body composition during the perioperative period and identifying risk factors for skeletal muscle mass loss in patients with colorectal cancer. The investigators will asess the impact of the type of anaesthesia (total intravenous anaesthesia/sevoflurane anaesthesia) for colorectal surgery on the muscle function and mass, which will be evaluated using ultrasound, dynamometry and bioimpedance.
For: Colorectal Cancer (CRC), Sarcopenia
One centre: Regional Institute of Oncology, Iaşi, Romania, Iași
No phaseSee the official record ↗NCT07237438
Original registry title
TIVA Versus Balanced Anesthesia on Muscle Mass in CRC Surgery
Observational studies · 2 studies
You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.
Observational registry: outcomes of endoscopic resection for digestive-tract tumours
This is a patient registry for all cases of pre-neoplastic or early neoplastic digestive tract lesions treated with curative intention by endoscopic submucosal dissection (ESD) technique.
For: Neoplasm, Stomach, Neoplasm, Colorectal, Neoplasm, Esophagus, Neoplasm, Duodenal
One centre: "Agrippa Ionescu" Hospital, București
Phase not statedSee the official record ↗NCT06033976
Original registry title
Endoscopic Submucosal Dissection Registry
Observational study: new screening and diagnostic methods for colorectal cancer
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologies would be low cost, breakthrough and of high sensitivity and specificity.
For: Colorectal Cancer
One centre: IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București, București
Phase not statedSee the official record ↗NCT06515821
Original registry title
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 15 Sept 2026.
